Organization | Jaseng Hospital of Korean Medicine

Jaseng Hospital of Korean Medicine Report issue

Academic/Hospital Phase 1 Phase 3

Founded: Seoul Korea, Republic of (1988)

Organization Overview

First Clinical Trial

2005

NCT02299739

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Jaseng Hospital of Korean Medicine | Jaseng Medical Foundation

Active Ingredients

Drugs in Phase 3 Trials (2)

hwangryun (1 trial)

sinbaro-3 (1 trial)

Drugs in Phase 1 Trials (1)

bee venom (7 trials)

Drugs in Other Trials (9)

chuna (6 trials)

diclofenac (voltaren) (1 trial)

eucommia ulmoides oliver extract (1 trial)

hifenac (1 trial)

loxoprofen (1 trial)

shinbaro (1 trial)

taheebo (1 trial)

talniflumate (1 trial)

tramadol (Ultram) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Back Pain (Phase 3)

Low Back Pain (Phase 3)

Radiculopathy (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial APIs: 12